ITEMS IN AFP WITH KEYWORD:
Key clinical questions and their evidence-based answers directly from the journal’s content, written by and for family physicians.
Jan 15, 2019 Issue
Intravenous Magnesium Sulfate for Acute Asthma Exacerbations [FPIN's Clinical Inquiries]
Patients presenting to the emergency department with an acute asthma exacerbation that has not responded to first-line therapy (bronchodilators and corticosteroids) can be treated effectively with intravenous magnesium sulfate.
Adding a LABA to an inhaled corticosteroid is safe but does not reduce the likelihood of a serious exacerbation requiring hospitalization. There is a small reduction in nonsevere asthma exacerbations, with one fewer exacerbation for every 53 patients treated for six months.
As-needed use of budesonide/formoterol is as effective as the daily use of maintenance budesonide plus as-needed terbutaline at preventing severe exacerbations, and results in a much lower cumulative steroid dose.
Nov 1, 2018 Issue
Culture-Specific Asthma Education Programs for Minority Groups [Cochrane for Clinicians]
In children from minority groups, culture-specific asthma education programs (CAEPs) reduce the number of severe asthma exacerbations requiring hospitalization and improve asthma control as measured by the Childhood Asthma Control Test but not the Asthma Control Questionnaire. CAEPs have no effect on overall asthma exacerbations in children.
Long-acting muscarinic antagonists added to inhaled corticosteroids are a superior treatment to placebo for improving asthma control in adults and children 12 years or older. Long-acting muscarinic antagonist add-on therapy is not superior to long-acting beta agonist (LABA) add-on therapy.
When compared with standard therapy (inhaled corticosteroids with or without LABAs and SABAs as relief therapy), SMART is associated with a reduced risk of acute asthma exacerbations in patients 12 years or older.
Jun 1, 2018 Issue
Combined Inhaled Short-Acting Beta2 Agonist and Anticholinergic Agents for Asthma [Medicine by the Numbers]
Although the quality of evidence included in this review was low to moderate, the potential benefits of decreased hospitalization and relapse rates and the comparatively mild and limited adverse events suggest that patients presenting with acute asthma exacerbations are likely to benefit from combin...
Learn the results of a Cochrane review which studied the effectiveness of Qvar in two sets of patients with chronic asthma: those receiving oral corticosteroids and those not receiving them.
Mar 1, 2018 Issue
Combination LABA Inhalers Compared with High-Dose Inhaled Steroids for Adults with Asthma [Medicine by the Numbers]
We designated the use of long-acting beta agonist inhalers for adults with asthma as having no benefits because of a small potential benefit of questionable clinical utility (avoiding a brief burst of oral steroids) and the possibility of a fatal harm. Find out more.